Interleukine-6 et métastases osseuses du cancer du rein : Bases moléculaires et implications thérapeutiques

Progres en Urologie

Volumn 11, Issue 2, 2001, Pages 368-375

  Paule, Bernard ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

BONE TUMOR; HUMAN; KIDNEY TUMOR; METASTASIS; PATHOLOGY; PHYSIOLOGY; REVIEW;

BONE NEOPLASMS; HUMANS; INTERLEUKIN-6; KIDNEY NEOPLASMS; RECEPTORS, INTERLEUKIN-6;

EID: 0035320050     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. AMIRA S., KISHIMOTO T. IL-6 and aNF-IL-6 in acute phase response and viral infection. Immunol Rev., 1992, 127, 25-28.
2. BAUMANN H., PROWSE K.R., MARINKOVIC S., WON K.A., JAHREIS G.P. Stimulation of hepatic acute phase response by cytokines and glucocorticoides. Ann. N.Y. Acad. Sci., 1989, 557, 280-285.
3. BLAY J.Y., NEGRIER S., COMBARET V., ATTALI S., GUILLOT E., MERROUCHE Y, MERCATELLO A., RAVAULT H., TOURANI J.M., MOSKOOTCKENKO J.F., PHILIP T., FAVROT M. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res., 1992, 52, 3317-22.
4. BLAY J.Y., PALLARDY A., RAVAUD S., NEGRIER S., DOUILLARD J.Y., CHEVREAU C., FLEURY J., RAY I., ESCUDIER B., LASSET C.for the French immunotherapy group-FNCLCC. Serum IL-6 , soluble gp80 IL-6 receptor and CRP in metastatic renal cell carcinoma (MRCC) treated with immunotherapy in the Crecy trial. Correlation to response. Ann Oncol., 1996, 7 (Suppl. 5), Abstr. 2540.
5. BLAY J.Y., PALLARDY M., RAVAUD A., CAUX C., NEGRIER S., DOUILLARD J.Y., CHEVREAU C., FLEURY J., RAY I., ESCUDIER B., LASSET C. for the French immunotherapy group-FNCLCC. Serum VEGF is an independent prognostic factor in patients with metastatic renal carcinoma treated with 1L-2 and /or IFN ; analysis of the CRECY trial. Proc. Am. Soc. Clin. Oncol., 1999, 18, 1669.
6. BROWN L.F., BERSE B., JACKMAN R.W., TOGNAZZI K., MANSEAU E.J., DVORAK H.F., SENGER D.R. Increased expression of the vascular permeability factor (vascular endothelial growth factor) and its receptor in kidney and bladder carcinoma. Am. J. Pathol., 1993, 143, 1255-1262.
7. CAMPBELL S.C. Advances in angiogenese research : relevance to urological oncology. J. Urol., 1997, 158, 1663-1674.
8. CAPPARELLI C., KOSTENUIK P.J., MORONY S., STARNES C., WEINMANN C., GWYNET V., SCULLY S., QI M., LACEY D.L., DUNSSTAN C.R. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res., 2000, 60 : 783-787.
9. CATLETT-FALCONE R., LANDOWSKI T.H., OSHIRO M.M., TURKSON J., LEVITTZKJ A., SAVINO R., CILIBERTO G., MOSCINSKI L., FERNANDEZ-LUNA J.L., NUNEZ G., DALTON N.S., JOVE R. Constitutive activation of Stat 3 signalling confers resistance to apoptosis in human U266 myeloma cells. Immunity., 1999, 10, 105-115.
10. CHAUHAN D., UCHIYAMA K., AKBARALI Y., URASHIMA M., YAMAMOTO K., LIBERMANN T.A., ANDERSON K.C. Multiple myeloma adhesion - induced interleukin 6 expression in bone marrow stroma cells involve activation of NF-kappa B. Blood., 1996, 87, 1104-1112.
11. CHOI H.R., KIM S.C., MOON N.C., MOON J.J. Inhibition of tumor growth and metastases of renal cell carcinoma by angiogenes inhibitor TNP-470. J. Urol., 1995, Part 2, 153, 402A, Abstr. 696.
12. COHEN T., NAHAN D., CEREM L.W.,NEUFELD G., NEUFELD B.Z. Interleukin-6 induces the expression of vascular endothelial growth factor. J. Biol. Chem., 1996, 12 : 736-774.
13. COSTES V., LIAUTARD J., PICOT M.C., ROBERT M., LEQUEUX N., BROCHIER J., BALDET P., ROSSI J.F. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J. Clin. Pathol., 1997, 50, 835-840.
14. DE LA MATA J., ULY H., GUISE T.A., STORY B., BOYCE B.F., MUNDY G.R., ROODINAR G.D. IL-6 enhances hypercalcemia and bone resoption mediated by PTH-rP in vitro. J. Clin. Invest., 1995, 95, 2846-2852.
15. DEMARTIS A., BERNASSOLA F., SAVINO R., MELINO G., CILIBERTO G. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res., 1996, 56, 4213-4218.
16. FUJIKA T., HASEYAWA M., OGIU K., MATSUSHITA Y., SATO M., KUBO T. Antitumoral effects of angiogenesis inhibitor O- (chloro acetliyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. J. Urol., 1996, 155, 1775-1180.
17. FUJIKAWA K., MATSUI Y., OKA H., FUKUZAWA S., TAKEUCHI H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J. Urol., 1999, 162, 1934-1937.
18. GRANDIS J.R., DRENNING S.D., CHAKRABORTY A., ZOU M.Y., PITT A.S., TWEARDY D.J. Requirement of stat 3 but not Stat 1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Invest., 1998, 102 : 1385-1392.
19. GUNNETT K., MOTZER R., ARNATO R., TODD M., POO W.J., COHEN R., BASELYA J., COOPER M., ROBERT F., FALCEY J., WAKSAL H. Phase II study of anti-epidermal growth factor receptor (EGFr) antibody C225 alone in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol., 1999, 18, 309.
20. GRUGEL S., FINKENZELLI G., WEINDEL K., BARLEON B., MARME D. Both v-ha-ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol. Chem., 1995, 270, 25915-25919.
21. GUISE T.A., YIN J.J., TAYLOR S.D., KUMOGAI Y., DALLAS M., BOYU D.F., MUNDY E.C. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest., 1996, 98, 1544-1549.
22. HOFBAUER L.C., LACEY D.L., DUNSTAN C.R., SPELLSBERG T.G., RIGGS B.L., KHOSLA S. Interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6 stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone, 1999, 25, 255-259.
23. HORI A., SASADA R., MATSUTAMI E., NAITO K., SAKUSA Y., MYTE T., KOZAI Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res., 1991, 51, 6180-6184.
24. HUGHES D.E., WRIGHT K.R., ULY H.L. Bisphosphonates promote apoptose in murine osteoclasts in vitro and in vivo. J. Bone Miner Res., 1995, 10, 1478-1487.
25. KAWANO M., HIRANO T., MATSUDA T., TAGA T., HORII Y., IWATO K., ASAOKI H., TARUG B., TANABE O., TANAKA H., KURAMOTO A., KISHIMOTO T. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 1988, 332, 83-85.
26. KENDALL R.L., WANG G., THOMAS K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor FTL-1 and its heterodimerizartion with KDR. Biochem. Biophys. Commun., 1996, 226, 324-328.
27. KIM K.J., LI B., WINER J., AMANINI M., GILLETT N., PHILLIPS M.S., LERRARA N.; Inhibilion of vascular endothelial growth factor-induced agiogenesis suppresses tumor growth in vivo. Nature, 1995, 362, 841-844.
28. KISHIMOTO T. The biology of interleukin-6. Blood, 1989, 74, 1-10.
29. KLEIN B., ZHANG X.G., JOURDAN M., CONTENT J., HARROUSSEAU F., AARDEN L., PIECHACZYK M., BATAILLE M. Paracrine rather than autocrin regulation of myeloma cell growth and differentiation by interleukin-6. Blood, 1989, 73, 517-526.
30. KOO A.S., ARMASTRONG C., BOCHNER B., SHIMABUKURO R., TSO C.L., DE KERNION J.B., BELLDEGRUN A. Production and regulation of interleukin-6 by renal cell carcinoma in vitro : protein activity and mRNA gene expression. Surg. Forum. 1990, 41, 710-713.
31. LACEY D.L., TIMMS E., TAN H.L., KELLEY M.J., DUNSTAN C.R., BURGESS T., ELLIOT R., COLOMBERO R., SCULLY S., HSU H., SULLIVAN J., HAWKINS N., DAVY E., CAPARELLI C., ELI A., OIAN Y.X., KAUFMAN S., SARON I., SHALHOUB V., SENALDI G., GUO J., DELANEY J., BOYLE W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell., 1998, 93, 165-176.
32. LAGNEAUX L., DELFORGE F., DORVAL C., BRON D., STRKMANS P. Excessive production of transforming groxth factor B by bone marow strma cells in B cell chronic lymphocytic leukemia inhibits the growth of hematopoietic precursors and interleukin 6 production. Blood , 1993, 82, 2379-2385.
33. LEVITSKI A., GAZIL A. Thyrosine kinase inhibition : an approach to drug development. Science, 1995, 267, 1782-1788.
34. MEYDAN N., GRUNBERGER T., DADI A., SHAHAR M., ARPAIA E., LAPIDOT Z. et al. Inhibition of acute lymphoblastic leukemia by a jak-2 inhibitor. Nature, 1996, 379, 645-648.
35. MIKI S., IWANO M., MIKI Y., YAMAMOTO M., TAIG B., YOKOKAWA K., SOANADA T., HORANO T., KISHIMOTO T. IL-6 functions as an autocrine growth factor in renal carcinoma. FEBS Letter, 1989, 250, 607-610.
36. MILLAUER B., LONGHI M.P., PLATE K.H., SHARWER L.K., RISAU W., ULRICH A., STRAWN L.M. Dominant negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res., 1996, 56, 1615-1620.
37. MORITA T., SHINOHARA N., TOKUE A. Antitumoral effect of a synthetic analogue of fumagillin on murine renal carcinoma. Brit. J. Urol., 1994, 74, 416-418.
38. MOTRO B., ILIN A., SACHS C., KESHET E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc. Natl. Acad. Sci. USA., 1990, 87, 3092-3096.
39. MOTZER R.J., BANDER N.H., NAMUS D.M. Renal cell carcinoma. N. Engl. J. Med., 1996, 12, 865-875.
40. MOTZER R.J., RUSSO P. Systemic therapy for renal cell carcinoma. J. Urol., 2000, 163, 408-415.
41. NEGRIER S., ESCUDIER B., LASSET C. Recombinant human interleukin 2, recombinant human interferon alfa-2a or both in metastatic renal cell carcinoma. Groupe Français d'immunothérapie. N. Engl. J. Med., 1998, 338 : 1272-1278.
42. OBIRI N.I., HILLEMAN R., HAAS G.P., SUDH S., PURI R.K. Expression of high affinity , interleukin-4 receptor in human renal carcinoma cells and inhibition of tumor growth in vitro by interleukin 4. J. Clin. Invest., 1993, 91 : 88-93.
43. OBIRI N.I., HSAIN R., DEBINSKI W., PURI R.K. Interleukin 13 inhibits growth of human renal carcinoma cells independently of the p140 interleukin 4 receptor chain. Clinical Cancer Res., 1994, 2, 1743-1749.
44. OGATA A., CHAUHAN D., TESH G., TREON S.P., URASHIMA M., SCHLOSSMAN R.L., ANDERSON K.C. IL-6 trigger cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol., 1997, 159, 2212-2221.
45. PAULE B., CLERC D., RUDANT C., COULOMBEL C., Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma. Hum. Pathol., 1998, 29 : 421-424.
46. PAULE B., CLERC D. Cancer du rein : métastases osseuses, immunothérapie et interleukine 6. Ann. Med. Int., 1999, 150, 4-9.
47. PAULE B., BELLOT J., RUDANT C., COULOMBEL C., ABBOU CC. Importance of IL-6 expression in primary human renal cell carcinoma : an immunohistochemical study. J. Clin. Path., 2000, 53 : 388-390.
48. PAULE B., CLERC D., BRION N. Les bisphosphonates en cancérologie. Nouv. Presse Med., 2000, 29, 723-729.
49. PAULE B., CLERC D., BONHOMME FAIVRE L., QUILLARD J., ABBOU CC. Significance of IL-6 expression in bone tumoral cells and serum levels of interleukin 6 in metastatic renal cell carcinoma. Soumis à publication dans Pathology.
50. RAK J., MITSUHASHI Y., BAYKO L. et al. Mutant ras oncogene upregulate VEGF/VPF expression; implications for induction and inhibition of tumor angiogenesis. Cancer Res., 1990, 55, 4575-4580.
51. RIZOLI R., BONJOUR T.P. High extracellular calcium increases the production of a parathyroid-hormone like activity by cultures leydig tumor cells associated with humoral hypercalcemia. J. Bone. Min. Res., 1989, 4, 839-844.
52. SASAKI A., BOYCE B.F., STORY B., WRIGHT K.R., CHAPMAN M., BOYCE R., MUNDY G.R., YONEDA T. Bisphosphonates rise-dronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res., 1995, 55, 3551-3557.
53. SENGER D.R., PERRUGI C.A., FEDER J., DVORAK H.F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res., 1986, 46 : 5629-5637.
54. SIMONET W.S., LACEY D.L., DUNSTAN C.R., KELLY M., CHANG M.S., LUTHY R., NGUYEN H.O., WOODEN S., BENNETT L., BOVNE T., SHIMAMOTO G., DeROSE M., ELIOTT R., COLOBERO A., TSAN H.L., TRAIL G., SULEVAN J., DAVY E., BUCARY N., RENSHAW-GEGG L., HUGUES T.M., HILL D., PATTISON W., CAMPBELL P., BOYLE W.J. Osteoprotegerin : a novel secreted protein involved in the regulation of hone density. Cell., 1997, 89, 309-319.
55. SIMONIAN P.L., GRILLOT A.M., NUNEZ G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood, 1997, 90, 1208-1216.
56. SINGH R.K., BUCANA C.D., GUTMAN M., FAN D., WILSON M.R., FIDLER I.J. Organ site dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Ann. J. Pathol., 145, 365-374.
57. SINGH R.K., GUTMAN M., BUCANA C.D., SANCHEZ R., LLANSA N., FIDLER I.J. Interferon alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinoma. Proc. Natl. Acad. Sci. USA., 1995, 92, 4562-4566.
58. STADLER W.M., KIZEL T., SCHAPIRO C., SOSMAN J., CLARK J., VOGELZANG N.J. Multi-instutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol., 1999, 17, 2541-2545.
59. TAKENAWA J., TANEKO Y., FUKUMOTO M., FUKUMOTO M., FUKATSU A., HIRANO T., FUKUGANA H., NAKAYAMA H., FUJITA J., YOSHIDA O. Enhanced expression of interleukin-6 in primary renal cell carcinoma. J. Natl. Cancer Inst., 1991, 83, 1668-1672.
60. TAKAHASHI A., SASAKI H., KIM S.J., TOBISU K., KALKIZOE T., TSUKAMOTO T., KUMAMOTO Y., SUGIMUA T., TERADA M. Markley increased amonts of messenger RNAs for vascular endothelial growth factor and placental growth factor in renal cell carcinomas associated with angiogenesis. Cancer Res., 1994, 54, 4233-4237.
61. TORTORA G., CIARDELLO F. Targeting of epidermoid growth factor receptor and protein A. Molecular basis and therapeutic applications. Ann. Oncol., 2000, 11 : 777-783.
62. TSUKAMOTO T., KUMAMOTO Y., MIAJO N., MASUMORY N., TAKAHASHI A., YANASE M. Interleukin-6 in renal cell carcinoma. J. Urol. 1992, 148, 1778-1782.
63. VARNER J.A., CHERRESH D.A. : Tumor angiogenesis and the role of vascular cell intergrin aVb3. In : De Vita E.D. Important advances in oncology. Philadelphia, H.S. Rosenberg Lippincott-Raven, 1996, pp. 69-87.
64. VENEULEN P.B., DIRISC L.Y., MARTIN M., LEMMENS J., VAN OSTERUM A.J. The predictive value of serum bFGF and VEGF in patients with metastalic renal cell carcinoma treated with interferon-2b. J. Natl. Cancer Inst., 199, 8 , 1317-1320.
65. WEISSGLAS M., SCHAMBART D.H.J., LOWICK C., PAPAPOULOS S., THEUNS H.M., KURTH K.H. Hvpercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal carcinoma implanted into nude mice. J. Urol., 1995, 155, 854-857.
66. WEISSGLAS M., SCHAMBART D.H.J., LOWIK C., PAPAPOULOS S., VOS P., KURTH K.H. The role of interleukin-6 in the induction of hypercalcemia in renal cell carcinoma transplanted into nude mice. Endocrinology. 1997, 138, 1879-1885.
67. ZHONG Z., WEN Z., DARNELL J.E. Jr. Stat 3 : a new family member that is activated through thyrosine phosphorylation in response to EGF and IL-6. Science, 1994, 264, 95-98.